ヒト免疫グロブリンの世界市場

ヒト免疫グロブリンの世界市場は2030年までに283億米ドルに達する見込み

2024年に170億米ドルと推定されるヒト免疫グロブリンの世界市場は、2024年から2030年にかけてCAGR 8.9%で成長し、2030年には283億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである自己免疫疾患アプリケーションは、CAGR 10.7%を記録し、分析期間終了時には126億米ドルに達すると予測されます。血液疾患アプリケーション分野の成長率は、分析期間中CAGR 6.5%と推定されます。

米国市場は46億米ドルと推定、中国はCAGR14.1％で成長予測

米国のヒト免疫グロブリン市場は、2024年に46億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに63億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは14.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.4%と8.5%と予測されています。欧州では、ドイツがCAGR 5.9%で成長すると予測されています。

世界のヒト免疫グロブリン市場- 主要動向と促進要因のまとめ

免疫関連疾患の拡大がヒト免疫グロブリンの使用をどのように形成しているか？

抗体を豊富に含む重要な血液由来製品であるヒト免疫グロブリンは、特に免疫不全や自己免疫疾患の管理など、幅広い治療分野でますます使用されるようになってきています。免疫関連疾患の世界の負担が増大するにつれ、医療関係者は免疫グロブリン療法を免疫補充と免疫調節の両方の目的で利用するようになってきています。一次性免疫不全症は、患者が十分な抗体を産生する能力を自然に欠く疾患であり、免疫グロブリン療法の最も一般的な適応症の一つです。このような場合、免疫グロブリン輸液は生命を脅かす感染症を予防し、長期的な健康状態を安定させるために極めて重要です。また、慢性炎症性脱髄性多発神経炎や重症筋無力症などの自己免疫性神経疾患の治療にも広く使用されており、過剰な免疫反応を制御するのに役立っています。さらに、化学療法、HIV、骨髄移植による二次性免疫不全もヒト免疫グロブリン療法で管理されており、その汎用性の高さが強調されています。このようなアプリケーションに関する医療提供者や患者の意識の高まりにより、病院、専門クリニック、在宅医療の現場での需要は着実に増加しています。病気に対する認識が高まり、診断能力が向上するにつれて、より多くの患者がこの治療法の候補として正しく認識されるようになり、ヒト免疫グロブリンに対する臨床的信頼がさらに強まっています。このような治療範囲の拡大は、免疫グロブリンの医学的意義を高めるだけでなく、持続的な市場成長の下地を作っています。

なぜ血漿採取と精製における技術革新が供給と安全性を高めるのか？

血漿採取と免疫グロブリン精製における技術革新は、これらの重要な治療法の信頼性、安全性、可用性を形成する上で変革的な役割を果たしています。ヒト免疫グロブリンの製造は、健康なドナーからの血漿採取から始まりますが、自動アフェレーシス装置の導入により、このプロセスの効率と収率の両方が改善されました。これらの機械は血漿成分の選択的抽出を可能にし、生産量を増加させながらドナーの疲労を軽減します。採取された血漿は、エタノール分画、クロマトグラフィー、ウイルス不活化などの工程を経て、病原体や不純物の除去を確実にするために厳密な精製が行われます。これらの工程は、最終製品の有効性を損なうことなく安全性を高めるために、絶えず改良されています。新しい濾過方法によって、メーカーはより高いレベルの純度を達成できるようになり、レシピエントにおける副作用のリスクを低減しています。さらに、コールドチェーンロジスティクスと包装の革新により、免疫グロブリン製剤の安定性と保存性が向上しており、冷蔵輸送へのアクセスが限られている地域では特に重要です。また、ヒト血漿が一次情報源であることに変わりはないが、多くの製造業者が組換え技術や代替発現系に投資しています。これらの進歩により、免疫グロブリンのサプライチェーンはより強固で拡張可能なものとなり、世界の需要の変動に対応できるようになってきています。血漿採取ネットワークの構築や拡大を目指す国が増える中、これらの技術は、世界中でより安全で効率的な免疫グロブリン療法を実現するための青写真を提供するものです。

ヘルスケア・インフラと政策イニシアチブは、免疫グロブリン療法への幅広いアクセスをどのように支えているか？

ヒト免疫グロブリン療法へのアクセスは、国のヘルスケア・イニシアチブ、国際的な協力関係、進化する償還制度によってますますサポートされています。高所得国では、免疫グロブリン療法は一般的に公的または民間の保険プランに含まれており、病院や外来診療施設での臨床使用が広く認められています。近年、中所得国の政府も、免疫グロブリンがしばしば過小診断される免疫関連疾患の治療に有用であることを認識し、必須医薬品リストに組み込み始めています。輸入品への依存を減らし、国内生産による入手可能性を向上させるため、血漿自給プログラムを実施している国もあります。官民パートナーシップや非営利団体は、特に血漿の収集や処理能力が歴史的に限られていた地域において、インフラ整備を促進しています。さらに、疾患別のアドボカシー団体は、タイムリーな診断と長期的な治療を優先する公平なアクセスと政策改革を推進する上で重要な役割を果たしています。標準化された治療ガイドラインや国際的な保健機関による最新のプロトコールも、免疫グロブリンをいつ、どのように使用すれば効果的であるかを世界中の医師が理解するのに役立っています。ヘルスケア専門家に対するトレーニングや教育の改善と診断ツールへのアクセスの向上により、患者はエビデンスに基づいた適応に基づく適切な治療を受けられるようになっています。このような体系的な取り組みにより、免疫グロブリン療法に対する従来の障壁が取り払われ、免疫グロブリン療法の適用範囲が三次病院だけでなく、小規模の診療所や地方の医療センターにまで拡大しつつあります。ヘルスケアシステムが成熟し、より包括的なものとなるにつれ、免疫グロブリンの使用を支えるインフラは、より信頼性が高く、公平で、世界標準のケアに沿ったものとなってきています。

ヒト免疫グロブリン市場の世界的拡大を促進する主な要因とは？

ヒト免疫グロブリン市場の世界の拡大は、需要の高まりとヘルスケアの優先事項の進化を反映した、医療、技術、人口統計、戦略的要因の合流によってもたらされています。主な促進要因の一つは、先天性・後天性免疫不全の有病率の増加であり、医療意識の向上とスクリーニング能力による診断率の上昇です。高齢者は感染症や自己免疫疾患にかかりやすく、免疫グロブリン療法の重要な受益者となっているためです。血漿の採取と分画技術の急速な進歩により、より安定したサプライチェーンが確保されています。これと並行して、迅速な承認と標準化された安全性要件により、新製品の市場参入が容易になるなど、規制の枠組みもより充実してきています。製薬会社はまた、在宅医療を支援し、治療のアドヒアランスを向上させる皮下製剤やその他の患者に優しい送達システムの開発にも注力しています。バイオ医薬品セクターにおける戦略的投資や合併は、特に新興経済圏において、より広範な流通網とより深い市場浸透を可能にしています。さらに、希少疾患や希少疾病用医薬品（オーファンドラッグ）への注目の高まりは、あまり一般的でない適応症に対するニッチな免疫グロブリン療法の技術革新を促しています。認知度向上キャンペーン、臨床トレーニング、政府支援が拡大し続ける中、ヒト免疫グロブリン市場は持続的な世界的成長を遂げ、信頼性の高い効果的なサポートを免疫系に必要とする患者にとって重要なソリューションを提供しています。

セグメント

用途（自己免疫疾患用途、血液疾患用途、炎症性疾患用途、感染性疾患用途、その他用途）、最終用途（病院最終用途、診療所最終用途、外来手術センター最終用途）

調査対象企業の例

• ADMA Biologics, Inc.
• Baxter International Inc.
• Bharat Serums and Vaccines Ltd
• Biotest AG
• Bio Products Laboratory Ltd（BPL）
• CSL Behring
• China National Pharmaceutical Group（Sinopharm）
• GC Pharma
• Grifols, S.A.
• Hualan Biological Engineering Inc.
• Intas Pharmaceuticals Ltd.
• Kedrion Biopharma
• LFB S.A.
• Octapharma AG
• Reliance Life Sciences
• Sanquin
• Shanghai RAAS Blood Products Co.
• Shire（Now part of Takeda）
• Sichuan Yuanda Shuyang Pharmaceutical Co.
• Takeda Pharmaceutical Company Ltd.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Human Immunoglobulin Market to Reach US$28.3 Billion by 2030

The global market for Human Immunoglobulin estimated at US$17.0 Billion in the year 2024, is expected to reach US$28.3 Billion by 2030, growing at a CAGR of 8.9% over the analysis period 2024-2030. Autoimmune Disorders Application, one of the segments analyzed in the report, is expected to record a 10.7% CAGR and reach US$12.6 Billion by the end of the analysis period. Growth in the Hematology Diseases Application segment is estimated at 6.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.6 Billion While China is Forecast to Grow at 14.1% CAGR

The Human Immunoglobulin market in the U.S. is estimated at US$4.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.3 Billion by the year 2030 trailing a CAGR of 14.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.4% and 8.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR.

Global Human Immunoglobulin Market - Key Trends & Drivers Summarized

How Is the Expanding Scope of Immune-Related Disorders Shaping the Use of Human Immunoglobulin?

Human immunoglobulin, a vital blood-derived product rich in antibodies, is increasingly being deployed across a wide range of therapeutic areas, particularly in the management of immune deficiencies and autoimmune disorders. As the global burden of immune-related diseases grows, medical professionals are turning to immunoglobulin therapy for both replacement and immunomodulatory purposes. Primary immunodeficiency disorders, where patients lack the natural ability to produce sufficient antibodies, are among the most common indications for these therapies. In such cases, immunoglobulin infusions are crucial for preventing life-threatening infections and ensuring long-term health stability. The product is also used extensively to treat autoimmune neurological diseases such as chronic inflammatory demyelinating polyneuropathy and myasthenia gravis, where it helps to regulate an overactive immune response. Furthermore, secondary immunodeficiencies caused by chemotherapy, HIV, or bone marrow transplantation are also being managed with human immunoglobulin therapy, highlighting its versatility. The growing awareness among healthcare providers and patients regarding these applications has resulted in a steady increase in demand across hospitals, specialty clinics, and home care settings. As disease awareness rises and diagnostic capabilities improve, more individuals are being correctly identified as candidates for this treatment, further reinforcing the clinical reliance on human immunoglobulin. This expanding therapeutic scope is not only elevating the medical significance of immunoglobulin but is also laying the groundwork for sustained market growth.

Why Are Technological Advancements in Plasma Collection and Purification Enhancing Supply and Safety?

Technological innovation in plasma collection and immunoglobulin purification is playing a transformative role in shaping the reliability, safety, and availability of these vital therapies. The production of human immunoglobulin begins with the collection of plasma from healthy donors, and the introduction of automated apheresis machines has improved both the efficiency and yield of this process. These machines allow for selective extraction of plasma components, reducing donor fatigue while increasing output. Once collected, the plasma undergoes rigorous purification involving processes such as ethanol fractionation, chromatography, and viral inactivation to ensure the removal of pathogens and impurities. These steps are continually being refined to enhance safety without compromising the efficacy of the final product. New filtration methods are allowing manufacturers to achieve higher levels of purity, reducing the risk of adverse reactions in recipients. Moreover, innovations in cold-chain logistics and packaging are improving the stability and shelf life of immunoglobulin preparations, especially important in regions with limited access to refrigerated transport. Many producers are also investing in recombinant technologies and alternative expression systems, though human plasma remains the primary source. These advancements collectively ensure that the supply chain for immunoglobulin is becoming more robust, scalable, and responsive to global demand fluctuations. As more countries seek to establish or expand their plasma collection networks, these technologies provide the blueprint for safer and more efficient immunoglobulin therapies worldwide.

How Are Healthcare Infrastructure and Policy Initiatives Supporting Broader Access to Immunoglobulin Therapy?

Access to human immunoglobulin therapy is being increasingly supported by national healthcare initiatives, international collaborations, and evolving reimbursement structures. In high-income countries, immunoglobulin is generally included in public or private insurance plans, allowing widespread clinical use in hospitals and outpatient care facilities. In recent years, governments in middle-income countries have also begun integrating immunoglobulin into essential medicines lists, recognizing its value in treating immune-related conditions that often go underdiagnosed. Some nations are implementing plasma self-sufficiency programs to reduce reliance on imported products and improve availability through domestic production. Public-private partnerships and nonprofit organizations are facilitating infrastructure development, especially in regions where plasma collection and processing capacity have been historically limited. Additionally, disease-specific advocacy groups have played a crucial role in pushing for equitable access and policy reforms that prioritize timely diagnosis and long-term treatment. Standardized treatment guidelines and updated protocols from international health bodies are also helping physicians around the world understand when and how to use immunoglobulin effectively. Improvements in training and education for healthcare professionals, combined with greater access to diagnostic tools, are ensuring that patients receive appropriate therapy based on evidence-based indications. These systemic efforts are breaking down traditional barriers to immunoglobulin therapy, expanding its reach beyond tertiary hospitals to smaller clinics and rural health centers. As healthcare systems continue to mature and become more inclusive, the infrastructure supporting immunoglobulin use is becoming more reliable, equitable, and aligned with global standards of care.

What Key Factors Are Driving the Global Expansion of the Human Immunoglobulin Market?

The global expansion of the human immunoglobulin market is driven by a confluence of medical, technological, demographic, and strategic factors that reflect growing demand and evolving healthcare priorities. One of the primary drivers is the increasing prevalence of immune deficiencies, both congenital and acquired, coupled with rising diagnostic rates due to improved medical awareness and screening capabilities. An aging global population is also contributing to market growth, as elderly individuals are more susceptible to infections and autoimmune conditions, making them key beneficiaries of immunoglobulin therapy. The rapid advancement of plasma collection and fractionation technology ensures a more stable supply chain, which is essential given the high resource intensity of immunoglobulin production. In parallel, regulatory frameworks are becoming more supportive, with expedited approvals and standardized safety requirements making it easier for new products to enter the market. Pharmaceutical companies are also focusing on the development of subcutaneous formulations and other patient-friendly delivery systems that support home-based care and improve treatment adherence. Strategic investments and mergers in the biopharmaceutical sector are enabling broader distribution networks and deeper market penetration, especially in emerging economies. Additionally, the growing focus on rare diseases and orphan drug incentives is encouraging innovation in niche immunoglobulin therapies for less common indications. As awareness campaigns, clinical training, and government support continue to expand, the human immunoglobulin market is positioned for sustained global growth, offering critical solutions for patients whose immune systems require reliable, effective support.

SCOPE OF STUDY:

The report analyzes the Human Immunoglobulin market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application, Other Applications); End-Use (Hospitals End-Use, Clinics End-Use, Ambulatory Surgery Centers End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• ADMA Biologics, Inc.
• Baxter International Inc.
• Bharat Serums and Vaccines Ltd
• Biotest AG
• Bio Products Laboratory Ltd (BPL)
• CSL Behring
• China National Pharmaceutical Group (Sinopharm)
• GC Pharma
• Grifols, S.A.
• Hualan Biological Engineering Inc.
• Intas Pharmaceuticals Ltd.
• Kedrion Biopharma
• LFB S.A.
• Octapharma AG
• Reliance Life Sciences
• Sanquin
• Shanghai RAAS Blood Products Co.
• Shire (Now part of Takeda)
• Sichuan Yuanda Shuyang Pharmaceutical Co.
• Takeda Pharmaceutical Company Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Human Immunoglobulin - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Primary Immunodeficiency Disorders Throws the Spotlight on Human Immunoglobulin as a Lifesaving Therapy
  • Growing Use in Autoimmune and Neurological Disorders Propels Demand for Intravenous and Subcutaneous Immunoglobulin
  • Here's the Story: Expanding Indications Beyond PID Strengthens the Business Case for Broader Immunoglobulin Utilization
  • Advancements in Plasma Fractionation Technologies Drive Supply Chain Efficiency and Product Innovation
  • Increasing Awareness and Diagnosis Rates Accelerate Demand Across Both Developed and Emerging Healthcare Markets
  • Here's How Aging Populations Fuel the Need for Immunoglobulin in Chronic Immune-Mediated Conditions
  • Plasma Collection Shortages and Donor Dependency Pose Long-Term Supply Challenges for the Immunoglobulin Market
  • Emergence of Subcutaneous Formulations Sustains Growth by Enabling Home-Based, Self-Administered Treatments
  • Global Expansion of Plasma Collection Centers Expands Addressable Supply and Geographic Market Reach
  • Improved Product Purity and Safety Profiles Drive Adoption Among Pediatric and Geriatric Patient Populations
  • Here's How Biotech Innovation Advances Recombinant Alternatives to Conventional Human-Derived Immunoglobulin
  • Rising Demand in Critical Care and Infectious Disease Management Opens New Emergency Use Scenarios
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Human Immunoglobulin Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Human Immunoglobulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Human Immunoglobulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Human Immunoglobulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Autoimmune Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Autoimmune Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Autoimmune Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Hematology Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Hematology Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Hematology Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Inflammatory Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Inflammatory Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Inflammatory Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Infectious Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Infectious Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Infectious Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 29: USA Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: USA 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: Canada 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: Canada 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• JAPAN
  • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 41: Japan Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: Japan 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Japan Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: Japan 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• CHINA
  • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 47: China Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: China Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: China 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 50: China Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: China Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: China 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• EUROPE
  • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Human Immunoglobulin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Human Immunoglobulin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Human Immunoglobulin by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Europe 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: Europe 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• FRANCE
  • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 62: France Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: France Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: France 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 65: France Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: France Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: France 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• GERMANY
  • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Germany Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: Germany 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 71: Germany Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Germany Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: Germany 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Italy Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Italy 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 77: Italy Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Italy Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Italy 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 80: UK Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: UK Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: UK 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 83: UK Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: UK Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: UK 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 86: Spain Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Spain Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: Spain 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 89: Spain Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Spain Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: Spain 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 92: Russia Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Russia Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: Russia 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 95: Russia Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Russia Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Russia 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Rest of Europe Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Rest of Europe 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Rest of Europe Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Rest of Europe 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Human Immunoglobulin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 105: Asia-Pacific Historic Review for Human Immunoglobulin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Asia-Pacific 16-Year Perspective for Human Immunoglobulin by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: Asia-Pacific 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Asia-Pacific Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: Asia-Pacific 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 113: Australia Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Australia Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: Australia 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 116: Australia Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Australia Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: Australia 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• INDIA
  • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 119: India Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: India Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: India 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 122: India Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: India Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: India 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 125: South Korea Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: South Korea Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: South Korea 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 128: South Korea Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: South Korea Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: South Korea 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Asia-Pacific Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Asia-Pacific Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 137: Latin America Recent Past, Current & Future Analysis for Human Immunoglobulin by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 138: Latin America Historic Review for Human Immunoglobulin by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Latin America 16-Year Perspective for Human Immunoglobulin by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 140: Latin America Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Latin America Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Latin America 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 143: Latin America Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Latin America Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Latin America 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 146: Argentina Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Argentina Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Argentina 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 149: Argentina Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Argentina Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Argentina 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 152: Brazil Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Brazil Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Brazil 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 155: Brazil Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Brazil Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Brazil 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 158: Mexico Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Mexico Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Mexico 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 161: Mexico Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Mexico Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Mexico 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Rest of Latin America Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Rest of Latin America 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Rest of Latin America Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: Rest of Latin America 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 170: Middle East Recent Past, Current & Future Analysis for Human Immunoglobulin by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 171: Middle East Historic Review for Human Immunoglobulin by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: Middle East 16-Year Perspective for Human Immunoglobulin by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 173: Middle East Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Middle East Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: Middle East 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 176: Middle East Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Middle East Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: Middle East 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 179: Iran Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Iran Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: Iran 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 182: Iran Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Iran Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: Iran 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 185: Israel Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Israel Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: Israel 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 188: Israel Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Israel Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Israel 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Saudi Arabia Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Saudi Arabia 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Saudi Arabia Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Saudi Arabia 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 197: UAE Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: UAE Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: UAE 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 200: UAE Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: UAE Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: UAE 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Middle East Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Rest of Middle East 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Middle East Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Rest of Middle East 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
• AFRICA
  • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 209: Africa Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Africa Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Africa 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 212: Africa Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Africa Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Africa 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION